All News

food healthy unhealthy beer alcohol salt

The folly of dietary restriction in contemporary gout?

Richard Conway, MBBChBAO, PhD

Gout has historically been considered a disease of the financially rich, rich in diet, and rich in alcohol.

Read Article
ACR Mon

ACR20 - Day 4 Report

Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
heart.jpg (keep)

FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat

Meral K. El Ramahi, MD, FACP, FACR

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc

Read Article
#BestACR20Tweets RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Video report from GCAN: Gout, Urate and the repositioning of innate immunity. NYU's Dr. Michael Pillinger promises deeper looks at #ACR20 activity regarding gout, but starts out reporting data from GCAN. https://t.co/PBglAlK4Dg https://t.co/OrPnCPHylD

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Bella Mehta reviews five gout-related abstracts presented at #ACR20 https://t.co/xTaw4HkD0c https://t.co/KVsVwJv3Fy

Links:

Dr. John Cush RheumNow ( View Tweet)
The #ACR20 convergence highlighted a shift in gout management and uric acid lowering therapy (ULT). Read more about mitigating immunogenicity when using uricase therapies as ULT in an article by Dr. Alexa Meara ( @lexmeara) https://t.co/5AfyFhJGqp https://t.co/Sv1BiI0Uwd

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/KfsFFX7z0D

Links:

Dr. John Cush RheumNow ( View Tweet)
Advanced Imaging for Crystal Arthritis: Which Test is Best? Dr. Nicola Dalbeth examines abstracts #0647 and #1542 involving imaging studies for crystal arthritis at #ACR20 https://t.co/g9wAJDPqrG https://t.co/28IcQORmFb

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/lNuzra5Raw

Links:

Dr. John Cush RheumNow ( View Tweet)
The #ACR20 convergence highlighted a shift in gout management and uric acid lowering therapy (ULT). Read more about mitigating immunogenicity when using uricase therapies as ULT in an article by Dr. Alexa Meara ( @lexmeara) https://t.co/MmO224139q https://t.co/iPcf7yENWf

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast out now on our site #ACR20 Mid-Meeting Recap: Psoriatic Arthritis, Gout Patient Outcomes on Low-Dose Steroids, Giant Cell Arteritis Panel Vaccination w/ Shingrix: Does it work for patients on JAKi? Is it safe? https://t.co/roc1Qjec5R https://t.co/gSkkj2Kl0m

Links:

Dr. John Cush RheumNow ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj

Links:

The Lancet TheLancet ( View Tweet)
The folly of dietary restriction in contemporary gout? by @RichardPAConway Dr. Conway discusses the abstracts presented at #ACR20 https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS

Links:

Dr. John Cush RheumNow ( View Tweet)
@RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/sQK4L7Zu76
Olga Petryna DrPetryna ( View Tweet)
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2

Links:

k dao KDAO2011 ( View Tweet)

IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020

Dr. John Cush RheumNow ( View Tweet)

Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated? #ACR20 @RheumNow

David Liew drdavidliew ( View Tweet)

GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×